Sorafenib is a multikinase inhibitor of Raf kinase, which is involved in cancer cell proliferation, and also of vascular endothelial growth factor receptor-2/-3 (VEGFR-2/-3) and platelet-derived growth factor receptor-beta (PDGFR-β), which are involved in peritumor neovascularization [40,41,42]. This evidence concerns the gene KDR and cancer.